A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury by Martens, An et al.
© 2017 Medical Gas Research | Published by Wolters Kluwer - Medknow28
RESEARCH ARTICLE 
A porcine ex vivo lung perfusion model with maximal argon 
exposure to attenuate ischemia-reperfusion injury
An Martens1, 2, Sofie Ordies1, 2, Bart M Vanaudenaerde2, 3, Stijn E Verleden2, 3, Robin Vos2, 3, Geert M Verleden2,3, 
Eric K Verbeken5, Dirk E Van Raemdonck2, 4, Sandra Claes6, Dominique Schols6, Matthieu Chalopin7, Ira Katz7,               
Geraldine Farjot7, Arne P Neyrinck1, 2,* 
1 Laboratory of Anesthesiology and Algology, Department of Cardiovascular Sciences, Katholieke Universiteit Leuven and University 
Hospitals, Leuven, Belgium
2 Leuven Lung Transplant Unit, Katholieke Universiteit Leuven, Leuven, Belgium
3 Laboratory of Pneumology, Department of Clinical and Experimental Medicine, Lung Transplant Unit, Katholieke Universiteit Leuven 
and University Hospitals, Leuven, Belgium
4 Laboratory of Experimental Thoracic Surgery, Department of Clinical and Experimental Medicine, Katholieke Universiteit Leuven and 
University Hospitals, Leuven, Belgium
5 University Hospitals Leuven, Department of Histopathology, Leuven, Belgium
6 Laboratory of Virology and Chemotherapy (Rega Institute), Department of Microbiology and Immunology, Katholieke Universiteit 
Leuven, Leuven, Belgium
7 Air Liquide Santé International Medical R&D; Paris-Saclay Research Center, Jouy-en Josas, France
*Correspondence to: Arne P Neyrinck, M.D., Ph.D., arne.neyrinck@uzleuven.be.
orcid: 0000-0002-4319-4285 (Arne P Neyrinck)
Argon (Ar) is a noble gas with known organoprotective effects in rodents and in vitro models. In a previous study we failed to find 
a postconditioning effect of Ar during ex vivo lung perfusion (EVLP) on warm-ischemic injury in a porcine model. In this study, we 
further investigated a prolonged exposure to Ar to decrease cold ischemia-reperfusion injury after lung transplantation in a porcine 
model with EVLP assessment. Domestic pigs (n = 6/group) were pre-conditioned for 6 hours with 21% O2 and 79% N2 (CONTR) or 
79% Ar (ARG). Subsequently, lungs were cold flushed and stored inflated on ice for 18 hours inflated with the same gas mixtures. 
Next, lungs were perfused for 4 hours on EVLP (acellular) while ventilated with 12% O2 and 88% N2 (CONTR group) or 88% Ar (ARG 
group). The perfusate was saturated with the same gas mixture but with the addition of CO2 to an end-tidal CO2 of 35-45 mmHg. The 
saturated perfusate was drained and lungs were perfused with whole blood for an additional 2 hours on EVLP. Evaluation at the end 
of EVLP did not show significant effects on physiologic parameters by prolonged exposure to Ar. Also wet-to-dry weight ratio did not 
improve in the ARG group. Although in other organ systems protective effects of Ar have been shown, we did not detect beneficial 
effects of a high concentration of Ar on cold pulmonary ischemia-reperfusion injury in a porcine lung model after prolonged exposure 
to Ar in this porcine model with EVLP assessment.
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IntroductIon
Lung transplantation is still hampered by a shortage of 
transplantable donor grafts, and those grafts that are 
available are often of limited quality.1 More and more, 
extended-criteria donor lungs are being used for organ 
transplantation. Although 1-year survival is similar,2 there 
is a higher incidence of severe primary graft dysfunction 
(PGD) among recipients of an extended-criteria donor lung.3 
PGD is the end-result of ischemia-reperfusion injury (IRI) 
affecting the integrity of the capillary-alveolar membrane 
leading to pulmonary oedema and impaired oxygenation.4,5 
Severe PGD is associated with an impaired short-term and 
long-term outcome.6 Therefore, there is a need to address 
PGD by improving donor lung quality, which is referred to 
as “reconditioning”. Organ reconditioning can be achieved 
at three different stages: prior to ischemic organ injury 
(preconditioning), during organ ischemia (percondition-
ing) or after onset of organ reperfusion (postconditioning). 
Preconditioning is known as classical donor management, 
perconditioning involves optimization of the “out of body” 
time (preservation) and postconditioning is seen as strate-
gies after reinstallation of perfusion.
Our previous study, which investigated a postcondition-
ing effect of argon (Ar) (and xenon (Xe)) on pulmonary 
ischemia-reperfusion injury, could not confirm such a 
positive reconditioning effect in lungs7; despite the fact 
that beneficial postconditioning effects of Ar have been 
shown in other injury models such as cardiac arrest,8,9 
brain injury,10 and neonatal asphyxia.11 The noble gases 
Ar and Xe have also previously been investigated as a 
reconditioning strategy in IRI kidney transplant models 
showing beneficial effects on graft function.12,13 But since 
the protective effect of Ar seems to be dose-dependent,14 
a higher and longer exposure to Ar to protect against pul-
monary ischemia reperfusion injury seemed justified. A 
prolonged exposure to Ar can be achieved by introducing 
the gas earlier in the process of organ donation.15 During 
prolonged ventilation of the donor, Ar might protect and 
precondition the pulmonary graft prior to the ischemic 
insult (“preconditioning”). In addition, the lung can be 
inflated with the potentially protective gas mixture during 
cold storage (“perconditioning”). Postconditioning can 
be achieved by ventilating the lung after implantation in 
the recipient or by administrating the gas during ex vivo 
lung perfusion (EVLP). EVLP can be considered as a plat-
form of reperfusion and preservation of the graft prior to 
transplantation. During EVLP, ventilating the donor lung 
prior to transplantation, in normothermic conditions with 
inhalational therapy is feasible.16,17 Also, the perfusion 
solution on EVLP could be saturated with an Ar mixture, 
as demonstrated with success in experimental perfusion 
of kidneys preceding transplantation.12,13 Replacing ni-
trogen (N2) with Ar in the gas mixture for the ventilator 
and for the gas exchanger in the EVLP system, results 
in a dual exposure of the pulmonary graft to Ar, on both 
the endothelial and epithelial sides (“postconditioning”).
This study investigated the effects of Ar on pulmonary 
ischemia-reperfusion injury when administered prior (precon-
ditioning), during (perconditioning) and after (postcondition-
ing) the ischemic insult to donor lungs. Normothermic EVLP 
was also used to evaluate the treatment on graft function.  
MaterIals and Methods
Animals 
Male domestic pigs n = 6/group (mean weight 35.7 kg, 
Topig 20, Zoötechnisch centrum KU Leuven, Lovenjoel, 
Belgium) were used following local ethical approval ob-
tained at the research institute (P043/2014). All animals 
received humane care in compliance with the “Principles 
of Laboratory Animal Care” formulated by the National 
Society for Medical Research and the “Guide for the Care 
and Use of Laboratory Animals” prepared by the Institute 
of Laboratory Animal Resources and published by the 
National Institutes of Health, USA (NIH Publication No. 
86-23, revised 1996).
Animal anaesthesia and study groups 
Anesthesia was induced with an intramuscular injection of 5 
mg/kg Zoletil 100 (Virbac, Carros, France) and 3 mg/kg xy-
lazine 2% (VMD, Arendonk, Belgium). After placement of 
an 18GA peripheral line (v. auricularis), muscle relaxation 
and analgesia were maintained with 2 mg pancuronium boli 
and 20 µg/kg/h fentanyl. Anesthesia was maintained with 
continuous infusion of 7-10 mg/kg/h propofol. Animals 
were intubated with a 7.0 mm endotracheal tube and ven-
tilated with a tidal volume (TV) of 8 mL/kg and 5 cmH2O 
positive end-expiratory pressure (PEEP). Respiratory rate 
was adjusted to obtain an end-tidal carbon dioxide (ETCO2) 
of 35-45 mmHg. Invasive arterial blood pressure (ABP) 
was measured in the right carotid artery and a 7.5 Fr Swan-
Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) 
was introduced through the right internal jugular vein to 
measure pulmonary pressures. Vigilance monitor (Edwards 
Lifesciences) was connected to monitor mixed venous 
saturation (SvO2) and continuous cardiac output (CCO). 
Animals (n = 6/group) were randomly divided into two 
groups: CONTR group and ARG group (Table 1). After 
baseline instrumentation, animals were preventilated 
(preconditioned) for 6 hours with either 21% O2/79% N2 
(CONTR group) or 21% O2/79% Ar (ARG group). The 
TV of 8 mL/kg was corrected for density differences in 
the ARG group with the following formula:                       
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The density of the test gas (21% O2/79% Ar) was 1.505 kg/m
3. 
Respiratory rate was adjusted to maintain an ETCO2 of 35-
45 mmHg. Every hour, lungs were recruited by increasing 
the PEEP temporarily from 5 cmH2O to 20 cmH2O. After 
6 hours of preconditioning, animals were heparinized 
(300 IU/kg) and 1 L blood was drained to be stored 
with citrate-phosphate-dextrose solution with adenine 
(CPDA, Sigma-Aldrich, Inc, St. Louis, MO, USA) at room 
temperature until the next day. Lungs were cold flushed 
antegradely (50 mL/kg) with OCS Solution (Transmedics, 
Andover, MA, USA) while ventilated with 7 mL/kg TV 
and 8 cmH2O PEEP. Lungs were then inflated with the 
same gas mixture used during the preconditioning phase, 
and clamped for preservation at 25 cmH2O. A retrograde 
flush was performed on the back table before storing the 
lungs on ice for a prolonged period of cold ischemia of 18 
hours. The following day, lungs were cannulated for EVLP 
with the XVIVO Lung Cannula Set (XVIVO Perfusion, 
Göteborg, Sweden) and an 8.0 mm endotracheal tube. A 
postconditioning (after the ischemic insult) exposure to Ar 
was introduced for 4 hours during acellular (OCS solution 
+ albumin) EVLP in a dual way (via ventilator and gas 
exchanger penetrating both epithelial and endothelial sides). 
In the ARG group, N2 was replaced by Ar in the gas mixture 
of the ventilator and the gas mixture of the gas exchanger. 
The gas mixture settings of the gas exchanger for Ar or N2 
(3 L/min) plus carbon dioxide (CO2) and oxygen (O2) were 
chosen to establish equilibrium in the oxygen content at the 
inflow and outflow with an ETCO2 of 25-35 mmHg. Lungs 
were ventilated with either 12% O2/88% N2 (CONTR) 
or 12% O2/88% Ar (ARG). In the ARG group, density 
corrections for the tidal volume with the test gas (12% 
O2/88% Ar) were calculated with the same formula (test 
gas density 1.533 kg/m3). Lungs were ventilated with a 
TV of 7 mL/kg, 7 breaths per minute respiratory rate and 
5 cmH2O PEEP. After 4 hours of postconditioning, an 
additional 2 hours of EVLP was performed to assess the 
lungs. Therefore, the acellular perfusate in the reservoir was 
drained and the system was primed with 1 L of whole blood 
(stored on CPDA at room temperature). During this 2-hour 
evaluation period, lungs were ventilated with air in both 
groups with 8 mL/kg TV, 12 times per minute. The perfusate 
was deoxygenated in the gas mixture using 10 L/min N2 
plus CO2 and O2 to obtain a mixed venous partial oxygen 
pressure with ETCO2 values between 25 and 35 cmH2O. 
A summary of the study protocol is presented in Table 1. 
Sampling, assessment and statistics
During the preconditioning phase in vivo, arterial 
blood samples were taken hourly. Also, the following 
hemodynamic parameters were monitored continuously 
and recorded hourly: arterial blood pressure (ABP), heart 
rate (HR), pulmonary artery pressure (PAP), SvO2, CCO 
measurement and central venous pressure (CVP). After 6 
hours of preconditioning, blood samples and tissue samples 
of liver and kidney (both fixed in formaldehyde 6%, 
embedded in paraffin and stained with haematoxylin-eosin) 
were taken to screen for potential injury due to toxicity of 
prolonged Ar exposure. 
Table 1: Protocol outline
Baseline
1 HR
Pre-conditoioning
6 HRS
Per-conditoioning
18 HRS
Post-conditoioning
4 HRS
Evalution
2 HRS
CONTR
Tidal volume
FiO2 ventilator
Gas mixer settings
8 mL/kg
AIR
-
8 mL/kg
AIR
-
Lungs stored inflated
AIR
-
7 mL/kg
12% O2/88% N2 
N2, CO2, O2 matching 
ventilation
8 mL/kg
AIR
N2, CO2, O2 
deoxygenation
ARG
Tidal Volume
FiO2 ventilator
Gas mixer settings
8 mL/kg
AIR
-
8 mL/kg
21% O2/79% Ar
-
Lungs stored inflated
21% O2/79% Ar
-
7 mL/kg
12% O2/88% Ar
Ar, CO2, O2 matching 
ventilation
8 mL/kg
AIR
N2, CO2, O2 
deoxygenation
Note: After baseline instrumentation, animals were pre-conditioned for 6 hours with 21% O
2
 and 79% N
2
 (CONTR) or 79% Ar (ARG). After the 
preconditioning, lungs were cold flushed and stored on ice for 18 hours. Then, lungs were perfused on ex vivo lung perfusion (acellular) for 4 hours 
while ventilated with 12% O
2
 and 88% N
2
 (CONTR) or 88% Ar (ARG). Meanwhile, the perfusate was saturated with the same gas mixture but with 
addition of CO
2
 to an end-tidal carbon dioxide of 35-45 mmHg. At last, the saturated perfusate was drained and lungs were perfused with whole blood 
for an additional 2 hours on ex vivo lung perfusion for evaluation. FiO
2
: Fraction of inspired oxygen; CO
2
: carbon dioxide; O
2
: oxygen;  N
2
: nitrogen; 
Ar: argon; HR(S): hour(s).
.
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lation were taken at the end of the protocol. A bronchoal-
veolar lavage (BAL) of 30 mL saline was performed in 
duplicate in the right middle lobe for cytokine analysis 
(Cytokine Swine Magnetic 7-plex Panel for Luminex, 
Thermo Fisher Scientific Inc, Waltham, MA, USA). 
Finally, the left lung was inflated at 25 cmH2O, frozen 
solid in liquid nitrogen vapours and scanned with Siemens 
Somaton computed tomography (CT) scanner (Siemens 
Healthcare, Erlangen, Germany). Lung mass, volume, and 
density were measured on the basis of the CT-scan, using 
imaging software (HorosTM) as previously described,20 in 
which the lung is manually delineated and the number of 
voxels and mean density of the voxels within the volume 
is determined. 
results
In vivo assessment 
During 6 hours of preconditioning in vivo, animals showed 
a stable and comparable CCO, SvO2, mean PAP (mPAP) and 
Ppeak in both the CONTR and the ARG groups (Figure 1). 
After 6 hours of preconditioning, during which animals 
in the ARG group were exposed for 6 hours to Ar through 
ventilation, serum analysis for kidney and liver function did 
not show an elevation in liver and kidney tests compared 
to control animals (Table 2). 
    During postconditioning and final evaluation on EVLP, 
physiological parameters were monitored and perfusate 
samples were taken hourly: partial oxygen pressure (PO2), 
left atrial pressure (LAP), pulmonary artery pressure 
(PAP), pulmonary vascular resistance (PVR), peak airway 
pressure (Ppeak). A two-way analysis of variance was used 
to compare physiological parameters and gas concentration 
in the perfusate during EVLP postconditioning. All data 
was analysed with Graphpad 4 (GraphPad Software Inc., 
La Jolla, CA, USA) and the level of statistical significance 
was set at P < 0.05.
Lung grafts were only evaluated at the end of the 
evaluation period and values were compared with a Mann 
Whitney test. Oxygenation was evaluated based on partial 
oxygen pressure over fractional inspired oxygen concentra-
tion (PaO2/FiO2). Tissue samples for histology were fixed 
in formaldehyde 6%, embedded in paraffin, stained with 
haematoxylin-eosin and scored based on injury severity 
by an experienced pathologist.18
Histological sections were scored from 0–3 based on 
severity of injury (injury severity score, ISS).19 The bron-
chovascular, pleuroseptal and alveolar compartment was 
scored individually for influx of neutrophils, mononuclear 
cells, presence of necrosis and congestion.  
Tissue samples for wet-to-dry weight ratio (W/D) calcu-
Figure 1: Continuous cardiac output (CCO), mixed venous saturation (SvO2), mean pulmonary artery pressures (mPAP) and peak ventilatory pressures 
(Ppeak) were monitored during the preconditioning period.  
Note: Results are depicted as median ± IQ range; CONTR: 6 hours ventilation with air; ARG: 6 hours ventilation with argon.
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Histology sections of the liver showed normal structure 
of liver lobules with no infiltration of inflammatory cells 
(Figure 2). Histology sections of the kidney showed intact 
glomeruli and normal proximal and distal tubuli. There 
was no infiltration of inflammatory cells or deposition of 
necrotic epithelial cells.  
Preservation on EVLP
During 4 hours postconditioning on EVLP, PO2 was stable 
and similar at the inflow and outflow indicating stable gas 
concentrations of the perfusate (Figure 3). 
During the postconditioning on EVLP, Ppeak and PVR 
remained stable in both groups and were not significantly 
different (Figure 4).
Evaluation of graft quality
After 2 hours of perfusion with whole blood, final evaluation 
Table 2: Liver and kidney serum tests
CONTR (n = 2) ARG (n = 6) P
Creatinine 
(mg/dL)
1.11(1.02-1.20) 0.98(0.88-1.05) 0.25
Ureum (mg/dL) 39.5(33.0-46.0) 21.0(18.25-24.0) 0.07
Alk fosf (U/L) 190.5(153.0-228.0) 118.5(99.5-163.5) 0.18
AST (U/L) 34.5(29.0-40.0) 30.0(25.0-34.0) 0.54
ALT (U/L) 38.5(28.0-49.0) 50.0(40.5-58.0) 0.29
Gamma GT (U/L) 59.5(56.0-63.0) 50.0(44.75-76.75) 0.57
LDH (U/L) 490.5(480.0-501.0) 525.5(425.5-575.3) 0.50
Bili (mg/dL) < 0.18 < 0.18 -
CRP (mg/L) < 0.3 < 0.3 -
Note: Normal parameters are shown for both groups. Results are 
depicted as median (IQ range). Alk fosf: Alkaline phosphatase; AST: 
aspartate transaminase; ALT: alanine aminotransferase; Gamma GT: 
gamma glutamyl transpeptidase; LDH: lactate dehydrogenase; Bili: total 
bilirubine; CRP: C-reactive protein; CONTR: 6 hours ventilation with 
air; ARG: 6 hours ventilation with argon.
Figure 2: Normal histology of the liver and kidney after 6 hours ventilation 
with argon (ARG) or air (CONTR).  
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Figure 3: Stable PO2 shown in out- and inflow.
Note: Results are depicted as median ± IQ range and analyzed with a two-way 
analysis of variance (no difference between both groups). EVLP: Ex vivo lung 
perfusion; NS: not significant.
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of physiologic parameters on EVLP did not show a signifi-
cant difference in PaO2/FiO2, Ppeak or PVR. Also, estima-
tion of lung oedema (W/D and CT-density) did not show 
a significant difference between the two groups (Table 3).
BAL total cell count and differential cell count (% of 
macrophages, neutrophils, lymphocytes) did not show a 
difference between both groups at the end of the evaluation 
on EVLP (Table 3). The sum of the ISS in the bronchovas-
cular, pleuroseptal and alveolar compartment was similar 
for congestion, necrosis, neutrophil influx and mononuclear 
cell influx in both groups (Table 3). Cytokine levels of 
porcine interferon-α (INF-α), interferon-γ (IFN-γ), tumor 
necrosis factor (TNF)-α, interleukin-8, interleukin-1β, 
interleukin-10 and interleukin-4 in BAL and perfusate are 
shown in Table 3. There were no significant differences 
between the CONTR and ARG group. 
dIscussIon
We report the results of a porcine study investigating the 
effect of prolonged exposure to Ar (prior, during and after 
ischemic insult) on cold-ischemic lung injury with ex vivo 
assessment. However, none of our investigated parameters 
could demonstrate a beneficial reconditioning effect on 
graft function.
Following a previous porcine pulmonary ischemia-
reperfusion injury study where no effect was found by 
postconditioning with Ar, we designed an experimental 
protocol to allow a maximal exposure to Ar. The pulmonary 
graft was therefore exposed to Ar prior to the ischemic 
interval (preconditioning), during the cold ischemic injury 
(perconditioning) and after the ischemic interval during 
reperfusion on EVLP (postconditioning). The concentration 
of oxygen in the gas mixture for lung ventilation (FiO2) was 
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Table 3: Final evaluation
CONTR ARG P
Physiology
PaO2/FiO2 365(337-567) 370(325-507) 0.79
Ppeak (cmH2O) 19.5(16.5-24.8) 18.5(15.8-22.8) 0.82
PVR (dynes×sec×cm-5) 628(473-827) 732(655-926) 0.24
Lung edema
Wet-to-dry weight 7.4(6.8-7.6) 7.5(7.1-8.1) 0.47
CT density (g/L) 262(219-302) 206(161-311) 0.18
BAL
Total cell count (×109 cells/mL) 1.75(0.92-3.17) 1.20(0.73-1.82) 0.47
Macrophages (% TCC) 90.9(84.2-93.0) 93.9(88.9-94.6) 0.39
Neutrophils (% TCC) 2.5(1.8-3.7) 2.2(1.2-3.8) 0.67
Lymphocytes (% TCC) 7.4(4.7-12.1) 4.8(3.9-6.4) 0.18
Histology
Mononuclear influx (ISS) 3.5(2.8-6.0) 1.0(1.0-3.8) 0.07
Congestion (ISS) 0.0(0.0-0.1) 0.4(0.0-0.5) 0.06
Necrosis (ISS) 0.0(0.0-0.0) 0.2(0.0-0.5) 0.18
Neutrophils (ISS) 0.1(0.0-0.6) 0.5(0.0-0.6) 0.57
Cytokines BAL
IFN-α 0.72(10-1,476) 0.72(0.71-0.86) 0.20
IFN-γ 0.17(0.15-0.20) 0.19(0.17-0.27) 0.39
TNF-α 0.03(0.03-69) 61(20-243) 0.11
IL-8 152(123-807) 525(214-1,730) 0.24
IL-1β, IL-10, IL-4 Below detection limit -
Cytokines perfusate
IL-1β 853(10-1,476) 1,957(1,484-2,352) 0.06
IL-10 25.0(1.2-130.6) 81.7(51.8-301.2) 0.13
IFN-α 1.4(1.0-3.0) 1.8(0.8-3.5) 0.62
IFN-γ 2.7(1.1-4.5) 3.0(1.3-11.2) 0.75
TNF-α 322(254-1,067) 833(5,664-7,477) 0.24
IL-8 904(386-127.6) 2,451(697-4,818) 0.09
IL-4 Below detection limit -
Note: No differences were found between both groups (Mann-Whitney testing) at the end of EVLP at the final evaluation of graft quality in physiological 
parameters, lung edema estimation, BAL cell count, injury severity scores (ISS) on histology, or cytokine levels in perfusate or BAL. PaO
2
/FiO
2
: 
Partial oxygen pressure/fractional inspired oxygen concentration; TCC: total cell count; ISS: injury severity score; BAL: bronchoalveolar lavage; IFN: 
interferon; IL: interleukin; TNF: tumor necrosis factor; CONTR: 6 hours ventilation with air; ARG: 6 hours ventilation with argon.
Figure 4: Stable airway peak pressures (Ppeak, left graph) and pulmonary vascular resistance (PVR, right graph) during postconditioning on ex vivo 
lung perfusion (EVLP). 
Note: Data are depicted as median ± IQ range and analyzed with a two-way analysis of variance (no differences between both groups).
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chosen, to obtain the highest concentration of Ar possible 
(or N2) without inducing hypoxia to the lung tissue. During 
the preconditioning phase, while the animal was still 
alive, the FiO2 of air was chosen (21%) and in the ARG 
group the N2 in air was replaced by 79% of Ar. To allow 
for perconditioning, the lungs were exposed to Ar during 
cold preservation by inflation with the same gas mixture 
used as during the preconditioning phase (FiO2 21% with 
79% N2 or Ar). The postconditioning phase during EVLP 
was optimized compared to the previous postconditioning 
protocol.7 Indeed: the oxygen concentration in the gas 
mixture of the ventilator was lowered to 12% instead of 21% 
to allow for a higher Ar concentration of 88% (or 88% N2 
in the CONTR group). And in addition, the perfusate was 
saturated with Ar via the gas exchanger to expose both the 
epithelial and the endothelial side of the alveolar membrane 
during EVLP. This kind of Ar-saturated perfusion solution 
has also been tested in experimental kidney perfusion 
leading to improved graft function after transplantation.12,13
During 6 hours of preconditioning with Ar in vivo, stable 
hemodynamic parameters were observed. Animals had 
normal pulmonary and systemic blood pressures, normal heart 
rates and normal peak ventilation pressures during the total 
perfusion time of 6 hours. After 6 hours of preconditioning, 
tissue samples from the kidney and liver were taken and the 
pathology report did not reveal any sign of injury to kidney 
or liver due to toxicity. Serum samples tested for liver and 
kidney function were similar between both groups. These 
preliminary findings confirm that prolonged ventilation with 
Ar in vivo is safe. 
Maintaining a steady state of oxygen delivery and gas 
exchange during preservation on EVLP is a technique that 
has been introduced by Transmedics in the OCSTM Lung 
protocol.21 In this set-up, partial oxygen concentration is 
kept stable at in- and outflow, therefore no gas exchange 
takes place. This allows for lower gas consumption since N2 
or Ar are not continuously washed out in the gas exchanger. 
This technique is chosen over the complete wash-out 
of oxygen with high flow rates of N2 or Ar, because of 
the scarcity and higher price of noble gases.22,23 During 
EVLP, we can monitor physiologic parameters over time 
while lungs are exposed to Ar and compare them with the 
physiologic parameters of the control group. 
To further assess the effect of Ar on IRI,4 after 4 hours of 
ex vivo postconditioning with Ar, lungs were perfused for an 
additional 2 hours with whole blood containing neutrophils. 
This concept attempted to mimic, transplantation; however, 
it could not replicate the complete in vivo environment. For 
example, the perfusion settings with a centrifugal pump 
result in a different shear stress environment and flow 
conditions when compared to the in vivo pulsatile cardiac 
reperfusion of the lung.
At the end of the 2-hour additional whole-blood perfusion 
period, the pulmonary graft was evaluated by comparing 
physiological data, tissue samples and BAL. A median W/D 
of 7.4 was observed in the CONTR group and no irreversible 
necrosis was seen on lung histology. In combination with 
an increased PVR and increased Ppeak, we can conclude 
that sufficient injury was inflicted to the lung graft by our 
injury model to study IRI. Surprisingly, no beneficial ef-
fect was detected in physiologic parameters (Ppeak, PVR, 
PaO2/FiO2), histology, BAL cell count and cytokine mea-
surements or lung edema (W/D and CT density) after pro-
longed exposure to argon in the ARG group. We therefore 
concluded that reconditioning of cold-ischemic injury by 
Ar is not beneficial in this setting. However, in other organ 
systems, both pre- and postconditioning benefits with Ar 
have been described and the mechanisms of these effects 
should be further investigated. 
Evidence of an organoprotective effect in solid organ 
transplantation has mainly been demonstrated in kidney 
transplantation. Both Faure et al.13 and Irani et al.12 showed 
that saturation of the cold preservation medium with argon 
resulted in a better preserved renal architecture with im-
proved early functional recovery, graft quality and survival 
after kidney transplantation in their rat and pig models, 
respectively. Niemann et al.24 showed that hypothermia 
alone, in brain-dead donors also results in a reduced rate of 
delayed graft function among kidney transplant recipients. 
The effect of hypothermia or noble gases alone, has not 
been thoroughly investigated in solid organ transplantation 
so far. It might be, that an organoprotective effect of noble 
gases in solid organ transplantation is based on an interac-
tion with the hypothermic protective effect. Mechanisms of 
a combinational therapy of hypothermia and noble gases, 
in combination with the interval of exposure (pre-, per-, 
postconditioning) should therefore be investigated further 
to demonstrate a protective effect in lung transplantation.
Enhancement of the neuroprotective effect of cooling by 
combining it with Ar exposure, has also been shown by 
Broad et al.25 who demonstrated improved brain energy 
metabolism, faster recovery on electroencephalogram 
and reduced cell death on terminal deoxynucleotidyl 
transferase dUTP nick end labelling in a new-born piglet 
encephalopathy model. Notably, the reported functional 
and histopathological neuroprotective effect in other 
traumatic, hypoxic and ischemic brain injury models has 
also been demonstrated in normothermic conditions.11,26-30 
A neuroprotective effect of noble gases can therefore not 
be explained by an augmented protective effect of hypo-
thermia alone. It might therefore still be possible that Ar 
could attenuate pulmonary injury other than (cold-) isch-
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Crit Care Med. 2012;40:1724-1730.
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of heterotopic autotransplantation. J Transl Med. 2016;14:40.
14. Brucken A, Kurnaz P, Bleilevens C, et al. Delayed argon ad-
ministration provides robust protection against cardiac arrest-
induced neurological damage. Neurocrit Care. 2015;22:112-
120.
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emic injury. For example, brain-dead donors suffer from a 
systemic inflammation and activation of apoptosis which 
could trigger the onset of severe IRI.31,32 Considering the 
mechanisms of brain-dead induced pulmonary damage 
and the potential of noble gases to promote extracellular 
signal-regulated kinase 1/2 signalling through activation 
of mitogen-activated protein kinase in both normothermic 
and hypothermic conditions,33,34 further animal research, 
preferably using a brain-dead injury model combined 
with protective hypothermia and transplantation, seems 
appropriate. 
These three main differences concerning in vivo reper-
fusion of the graft, combination of noble gases with hy-
pothermia and a different injury model (e.g., brain death) 
could be the reason why argon did not improve pulmonary 
graft function in our model while in other organ systems a 
protective effect has been described. 
We conclude that, although beneficial effects of Ar on 
ischemic injury in various other organ systems have been 
reported, we did not detect an improvement in pulmonary 
graft function after prolonged exposure to Ar in our cold-
ischemic injury model with EVLP assessment. Further 
animal research, preferably using a brain-dead injury model, 
including an in-depth mechanistic investigation of the lung-
protective effect of Ar, should be conducted.  
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